CASE 2 58 yo man IVDU in past….last used 35 yrs ago Genotype 1a Chronic Hepatitis C Type II Diabetes Private drug plan coverage.

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

Advertisements

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

Management of non naïve patients with hepatitis C Relapsers Alessandra Mangia Liver Unit & Division of Gastroenterology “CSS” San Giovanni Rotondo, Italy.

CASE 2 48 yo man IVDU in past….last used 27 yrs ago Stable social situation Currently receiving social assistance with provincial drug coverage No comorbid.

Liver Disease and Thalassaemia George Constantinou.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in GT 1-6 (Flat versus Weight-Based Ribavirin Dosing) WINR Study Phase 3 Treatment.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Hepatitis web study Hepatitis web study Sofosbuvir, Ribavirin, GS-0938 in GT 1-4 QUANTUM Phase 2b Treatment Naïve Lalezari JP, et al. EASL. 2013; Abstract.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.

Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.

Hepatitis web study Hepatitis web study Duration and Dose Finding Peginterferon alfa-2a + Ribavirin Phase 3 Treatment Naïve, Chronic HCV Randomized study.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3 Phase 3 Treatment Naïve, Chronic HCV Mangia A, et.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study WINR Study Flat versus Weight-Based Ribavirin Dosing Phase 3 Treatment Naïve, Chronic HCV Jacobson IM, et. al.

Hepatitis C Genotype 3 Paris 2012 Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.

Hepatitis web study Hepatitis web study Simeprevir in HIV Coinfection, GT-1 C212 Trial Phase 3 Treatment Naïve and Treatment Experienced Dieterich D, et.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 2 Robert G. Gish MD Staff Physician, Stanford University.

Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.

Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.

Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

LONG-TERM OUTCOME OF INTERFERON/RIBAVIRIN TREATMENT IN GERMAN REAL-LIFE SETTING: DURABLE SVR ASSOCIATED WITH LOW RATES OF LIVER-RELATED EVENTS S. Mauss.

VIRTUAL MEDZONE Your Resource for Hepatitis Related Innovative Medical Communication.

F, 66y/o, physical check 11. Ans : Intrathoracic goiter.

CASE 3 63 yo man HIV positive G1a chronic Hepatitis C… Recent HIV history TDF/FTC/RTV/Atazanavir with CD4 480 and HIV viral load

HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,

Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

New Treatment Paradigms for Therapeutically-Naïve and Treatment-Experienced HIV Patients A Customized CME Learning Experience.

Alessio Aghemo First Division of Gastroenterology Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Università degli Studi di Milano 5 th Paris.

LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.

Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.

Hepatitis web study Hepatitis web study Simeprevir with Peginterferon and Ribavirin in GT-4 RESTORE Phase 3 Treatment Naïve and Treatment Experienced Moreno.

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs CD4 310/40% HIV Viral Load

Hepatitis C When, how and which patients should be treated Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.

Hepatitis B By James Korbach.

Hepatitis-2015 Orlando, USA July

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Genotype 1 NIAID/NIH Trial Phase 2, Treatment Naïve Treatment Naïve (unfavorable.

CASE 3 62 yo man Genotype 1b chronic hepatitis C Cirrhosis No previous ascites/encephalopathy OGD revealed a few very small esophageal varices.

WEEK 1 You have 10 seconds to name…

Hepatitis C Nonresponders

Hepatitis web study Hepatitis web study Boceprevir with PEG + RBV in Genotype 1 SPRINT-1 Phase 2 Treatment Naïve Kwo PY, et al. Lancet. 2010;376:

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs. ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs. CD4 310/40% HIV Viral Load

CASE 2 54 yo man…HIV PCP Cryptospordiasis Chronic HepC Genotype 1a Biopsy… 2/4 activity, 3/4scarring CD4 40 No baseline genotype.

CASE 1 54 yo man HIV positive 8 yrs ago Tenofovir/FTC/RTV/Atazanavir x 4 yrs Previously documented NNRTI resistance with Y181C, G190A,and mixed m184v/wt.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon+ Ribavirin in HCV-HIV GT 1-4 Phase 2 Rodriguez-Torres M, et al. J Acquir Immune Defic.

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney.

Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH

Treatment for Hepatitis C through Washington Apple Health Elisabeth S. Smith Northwest Health Law Advocates June 3, 2016.

CASE 4 44 yo man HIV positive 2010 CD4 400 on diagnosis Initiated Abacavir/3TC/Dolutegravir in /2013 CD4 600 HIV viral load

Role of Ministry of Health and Medical Education in management and control of Hepatitis C 2016/07/13.

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Viral Hepatitis Graham R Foster Professor of Hepatology

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

The changing landscape of hepatitis infection

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Complicated cases David Fletcher, MD Department of Medicine University of Toronto.

Talking to Patients About HCV Treatment

Treating Hep C with Novel Agents

More Than Treatment.

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.

HCV Protease Inhibitors in Clinical Practice

Hepatitis C: After the Diagnosis

HCV Protease Inhibitors in Clinical Practice

Presentation transcript:

CASE 2 58 yo man IVDU in past….last used 35 yrs ago Genotype 1a Chronic Hepatitis C Type II Diabetes Private drug plan coverage

CASE 2 Hepatitis C history 2005 Liver Biopsy…gd 2 activity and gd 3-4 fibrosis Treated with Peg Inf/RBV 1000mg/day (70kg) Seemingly adherent

CASE 2 Hepatitis C history 2005/6 Week 0 HCVRNA..1.16x10E6 Week 4 HCVRNA…3.65 x 10E4 Week 12 HCVRNA…1.08x 10E2 Week 24 HCVRNA…undetectable Week 48 HCVRNA…undetectable 3 months post therapy F/U…5.90 x 10E5

CASE 2 Would you retreat… What would be the projected chance of cure Is he a candidate for response guided therapy… How long would you treat with each agent